Malaria Vaccine Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type of Vaccine (Protein Vaccine, DNA Vaccines, Others), By Target (Pre-Erythrocytic Stage, Erythrocytic Stage, Combined Vaccines), By End user (Hospitals, Vaccination Centres, Others) and Region Forecast 2020-2031

Malaria Vaccine Market size was valued at US$ 108.4 million in 2024 and is expected to reach US$ 798.0 million by 2031, growing at a significant CAGR of 33% from 2025-2031. Malaria is an infectious parasitic disease transmitted by a vector, female anopheles mosquito. Malaria produces recurrent attack of fever and chills. Malaria may lead to chronic conditions often death. Malaria may lead to several complications such as respiratory distress, severe headache and others.

Generally, malaria is diagnosed by the blood tests by investigating symptoms and presence of parasite in blood. Malaria diseases are widely spread in tropical and subtropical regions around the equator. Malaria's prevalence in tropical nations has been a source of concern for the entire world, causing millions of fatalities during the last ten years. Vaccine development is an essential component of effective intervention control.

In recent years, there has been a lot of study into new vaccine options. A diversified pipeline has been studied, based on ongoing malaria life-cycle research. Understanding the biology of the deadly human malaria parasites Plasmodium falciparum and Plasmodium vivax is critical for expanding opportunities in the malaria vaccine industry. New options in the malaria vaccine business have opened up thanks to generations of pre-erythrocytic vaccinations. This has sparked a flurry of interest from biotech firms. RTS,S/AS01 (RTS,S) is the most thoroughly investigated vaccine option for P. falciparum malaria prophylaxis.  

Key Developments:

• In November 2024, Sudan launched its first malaria vaccination campaign. This campaign is taking place amidst an ongoing civil conflict of 18 months and aims to protect thousands of children from this deadly disease.
• In October 2024, the Democratic Republic of the Congo (DRC) achieved a significant public health milestone by successfully integrating the malaria vaccine into its national routine immunization program. This initiative was officially launched in Mbanza-Ngungu, located in the southwest of the country, by the Minister of Public Health, Hygiene and Social Welfare, with the active participation of the Governor of Kongo-Central. The launch was supported by key partners, including the World Health Organization (WHO), the United Nations Children's Fund (UNICEF), Gavi, the Vaccine Alliance, PATH, Clinton Health Access Initiative (CHAI), PMI, Breakthrough ACTION, and SANRU, among others.
• In May 2024, the Serum Institute of India, the world's largest vaccine manufacturer by volume, reached a milestone by shipping its first doses of the R21/Matrix-M™ malaria vaccine to Africa. The initial shipment is destined for the Central African Republic (CAR), with subsequent deliveries planned for other African nations, including South Sudan and the Democratic Republic of Congo, in the near future. Of the 163,800 doses allocated for CAR, 43,200 doses were shipped from the Serum Institute of India's facility on this initial delivery.